Daniel Louis Price

Daniel Louis Price

Auto-generated profile, based on publicly available information

Daniel Louis Price

Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, MN 55905, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
EMEric J. Moore
Eric J. Moore
SOSteven M. Olsen
Steven M. Olsen
RLRebecca R. Laborde
Rebecca R. Laborde
JGJoaquín J. García
Joaquín J. García
FWFrancis J. Walsh
Francis J. Walsh
KOKerry D. Olsen
Kerry D. Olsen

1 December 2008 in Otolaryngologic Clinics of North America
Verified
Journal Article
Closed access
DPDaniel L. Price
Daniel L. Price
RWRichard J. Wong
Richard J. Wong
GRGregory W. Randolph
Gregory W. Randolph

31 March 2021 in Head & Neck
Verified
Journal Article
Closed access
PDF file
MMMatthew M. May
Matthew M. May
BHBenjamin M. Howe
Benjamin M. Howe
TOThomas J. O'Byrne
Thomas J. O'Byrne
AAAmy E. Alexander
Amy E. Alexander
JMJonathon M. Morris
Jonathon M. Morris
DPDaniel L. Price
Daniel L. Price

1 March 2018 in Surgical Oncology
Verified
Journal Article
Closed access
JSJohn R. Sims
John R. Sims
Travis E GrotzTravis E Grotz
Travis E Grotz
BPBarbara A. Pockaj
Barbara A. Pockaj
RJRichard W. Joseph
Richard W. Joseph
RFRobert L. Foote
Robert L. Foote
DPDaniel L. Price
Daniel L. Price

1 July 2012 in American Journal of Otolaryngology
Verified
Journal Article
Closed access
SOSteven M. Olsen
Steven M. Olsen
EMEric J. Moore
Eric J. Moore
CKCody A. Koch
Cody A. Koch
DPDaniel L. Price
Daniel L. Price
JKJan L. Kasperbauer
Jan L. Kasperbauer
KOKerry D. Olsen
Kerry D. Olsen

1 March 2008 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SLShu-Fu Lin
Shu-Fu Lin
SGSizhi Paul Gao
Sizhi Paul Gao
DPDaniel L. Price
Daniel L. Price
SLSen Li
Sen Li
TCTing-Chao Chou
Ting-Chao Chou
RWRichard J. Wong
Richard J. Wong
Purpose: Novel therapeutic regimens are needed to improve the dismal outcomes of patients with anaplastic thyroid cancer (ATC). Oncolytic herpes simplex virus have shown promising activity against human ATC. We studied the application of oncolytic herpes simplex virus (G207 and NV1023) in combination with currently used chemotherapeutic drugs (paclitaxel and doxorubicin) for the treatment of ATC. Experimental Design and Results: All four agents showed dose-response cytotoxicity in vitro for the human ATC cell lines KAT4 and DRO90-1. G207, combined with paclitaxel, showed synergistic cytotoxicity. Chou-Talalay combination indices ranged from 0.56 to 0.66 for KAT4, and 0.68 to 0.74 for DRO90-1 at higher affected fractions. Paclitaxel did not enhance G207 viral entry and early gene expression or G207 viral replication. Paclitaxel combined with G207 compared with single-agent treatment or controls showed significantly increased microtubule acetylation, mitotic arrest, aberrant chromatid separation, inhibition of metaphase to anaphase progression, and apoptosis. A single i.t. injection of G207 combined with biweekly i.p. paclitaxel injections in athymic nude mice bearing KAT4 flank tumors showed significantly reduced mean tumor volume (74 ± 38 mm3) compared with G207 alone (388 ± 109 mm3), paclitaxel alone (439 ± 137 mm3), and control (520 ± 160 mm3) groups at 16 days. There was no morbidity in vivo attributable to therapy. Conclusions: Mechanisms of paclitaxel antitumoral activity, including microtubule acetylation, mitotic block, and apoptosis, were enhanced by G207, which also has direct oncolytic effects. Combination of G207 and paclitaxel therapy is synergistic in treating ATC and holds promise for patients with this fatal disease.